NASDAQ:ARDS Aridis Pharmaceuticals - ARDS Institutional Ownership Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.38 -0.01 (-2.51%) (As of 03/28/2023 10:11 AM ET) Add Compare Share Share Today's Range$0.38▼$0.3950-Day Range$0.36▼$1.3052-Week Range$0.35▼$2.77Volume25,711 shsAverage Volume1.67 million shsMarket Capitalization$11.44 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Aridis Pharmaceuticals (NASDAQ:ARDS)CurrentInstitutional OwnershipPercentage10.89%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$3.65 MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$11,000.00 Skip Chart & View Institutional Buying and Selling Data ARDS Institutional Buying and Selling by Quarter Get ARDS Insider Trade Alerts Want to know when executives and insiders are buying or selling Aridis Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Aridis Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/15/2023Armistice Capital LLC2,068,000$2.44M0.0%N/A9.938% 12/2/2022EP Wealth Advisors LLC50,000$47K0.0%N/A0.240% 11/15/2022State Street Corp43,247$40K0.0%+54.2%0.244% 7/19/2022Commonwealth Equity Services LLC567,200$0.62M0.0%-1.7%3.205% 5/13/2022Vanguard Group Inc.524,122$0.92M0.0%+3.3%2.961% 5/12/2022Group One Trading L.P.27,066$48K0.0%N/A0.153% 5/4/2022Commonwealth Equity Services LLC577,200$1.02M0.0%+2,757.4%3.261% 4/14/2022Minot Wealth Management LLC50,000$88K0.0%N/A0.356% 1/31/2022Commonwealth Equity Services LLC20,200$47K0.0%N/A0.144% 11/12/2021AIGH Capital Management LLC150,591$0.55M0.1%-67.2%1.243% 11/9/2021BlackRock Inc.42,227$0.16M0.0%+33.6%0.348% 11/9/2021Wealth Architects LLC14,077$52K0.0%N/A0.116% 8/13/2021Vanguard Group Inc.159,946$1.18M0.0%+6.9%1.424% 8/12/2021AIGH Capital Management LLC459,261$3.33M0.6%+8.5%4.088% 7/19/2021Minot Wealth Management LLC25,000$0.15M0.0%-65.4%0.223% 5/19/2021Worth Venture Partners LLC105,413$0.62M0.3%+19.9%0.938% 5/18/2021Perritt Capital Management Inc.10,100$60K0.0%N/A0.090% 5/7/2021BlackRock Inc.26,381$0.16M0.0%+11.4%0.296% 4/29/2021Minot Wealth Management LLC72,230$0.43M0.1%-45.4%0.643% 2/17/2021Worth Venture Partners LLC87,932$0.53M0.4%N/A0.874% 1/28/2021Minot Wealth Management LLC132,283$0.80M0.2%N/A1.314% 11/6/2020BlackRock Inc.22,600$0.16M0.0%+15.1%0.253% 11/27/2019Millennium Management LLC25,569$0.17M0.0%N/A0.287% 8/14/2019Vanguard Group Inc.43,281$0.44M0.0%-5.2%0.534% 2/15/2019Millennium Management LLC12,112$0.13M0.0%-48.6%0.149% (Data available from 1/1/2016 forward) ARDS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ARDS shares? During the previous two years, 12 institutional investors and hedge funds held shares of Aridis Pharmaceuticals. The most heavily invested institutionals were Armistice Capital LLC ($2.44M), Vanguard Group Inc. ($0.92M), Commonwealth Equity Services LLC ($0.62M), Worth Venture Partners LLC ($0.62M), AIGH Capital Management LLC ($0.55M), BlackRock Inc. ($0.16M), and Minot Wealth Management LLC ($88K).Learn more on ARDS's institutional investors. What percentage of Aridis Pharmaceuticals stock is owned by institutional investors? 10.89% of Aridis Pharmaceuticals stock is owned by institutional investors. Learn more on ARDS's institutional investor holdings. Which institutional investors have been buying Aridis Pharmaceuticals stock? Of the 12 institutional investors that purchased Aridis Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($2.07M), Commonwealth Equity Services LLC ($0.58M), EP Wealth Advisors LLC ($50K), Minot Wealth Management LLC ($50K), AIGH Capital Management LLC ($35.90K), Vanguard Group Inc. ($27.07K), and Group One Trading L.P. ($27.07K). How much institutional buying is happening at Aridis Pharmaceuticals? Institutional investors have bought a total of 2,905,417 shares in the last 24 months. This purchase volume represents approximately $4.30M in transactions. Which Aridis Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Aridis Pharmaceuticals stock in the last 24 months: AIGH Capital Management LLC ($0.31M), Minot Wealth Management LLC ($0.11M), and Commonwealth Equity Services LLC ($10K). How much institutional selling is happening at Aridis Pharmaceuticals? Institutional investors have sold a total of 425,953 shares in the last 24 months. This volume of shares sold represents approximately $1.85M in transactions. This page (NASDAQ:ARDS) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.